Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the impact of nutritional status at allogeneic stem cell transplantation on clinical outcomes.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026
Same author

Resminostat for maintenance treatment in patients with advanced-stage mycosis fungoides or Sézary syndrome: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026
Same author

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO.

Blood advances·2025
Same author

Extranodal natural killer/T-cell lymphoma nasal type in a western population: Molecular profiling identifies new therapeutic targets.

American journal of hematology·2023
Same author

Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.

Frontiers in immunology·2022
Same author

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022

Related Experiment Video

Updated: Jul 9, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.7K

Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Eva Gonzalez Barca1

  • 1Hematology Department, Catalan Institute of Oncology-IDIBELL, University of Barcelona, 08908 Barcelona, Spain.

Journal of Clinical Medicine
|December 9, 2023
PubMed
Summary

New treatments are being developed for relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL), as current therapies are not effective for all patients. This review highlights promising new options for this aggressive cancer.

Keywords:
diffuse large B-cell lymphomaefficacyrelapsed/refractorytherapytoxicity

More Related Videos

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Related Experiment Videos

Last Updated: Jul 9, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.7K
Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.0K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive hematologic malignancy with significant heterogeneity.
  • Approximately 40% of DLBCL patients face disease relapse or resistance to initial chemoimmunotherapy.
  • Despite advancements, a critical unmet need persists for patients with relapsed/refractory (R/R) DLBCL.

Purpose of the Study:

  • To review emerging therapeutic strategies for R/R DLBCL.
  • To highlight novel treatments currently in clinical development.
  • To address the ongoing challenges in managing R/R DLBCL.

Main Methods:

  • Literature review of recent clinical trials and research publications.
  • Focus on novel agents and therapeutic modalities for R/R DLBCL.
  • Analysis of data on efficacy and safety of investigational therapies.

Main Results:

  • Several new therapeutic agents show promise for R/R DLBCL.
  • Approved therapies include anti-CD19 CAR T-cell, polatuzumab, and tafasitamab.
  • Ongoing research focuses on overcoming resistance and improving outcomes.

Conclusions:

  • Despite progress, R/R DLBCL remains a significant clinical challenge.
  • Emerging therapies offer new hope for patients unresponsive to current treatments.
  • Continued research is crucial to develop more effective R/R DLBCL treatments.